BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

908 related articles for article (PubMed ID: 17382165)

  • 21. [Clinical studies of testicular tumor. I. Analysis of 27 patients with seminoma: the clinical significance of hCG-beta determination and of retroperitoneal lymph node dissection for stage I patients].
    Tsukamoto T; Kumamoto Y; Ohmura K; Tsunekawa T; Yamazaki K
    Hinyokika Kiyo; 1986 Jul; 32(7):989-97. PubMed ID: 2430436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
    Yoon GH; Stein JP; Skinner DG
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):75-85. PubMed ID: 15757440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancer.
    Williams SB; Kacker R; Winston D; Bahnson E; Steele GS; Richie JP
    J Urol; 2011 Dec; 186(6):2245-8. PubMed ID: 22014805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concordance and prediction ability of original and reviewed vascular invasion and other prognostic parameters of clinical stage I nonseminomatous germ cell testicular tumors after retroperitoneal lymph node dissection.
    Nicolai N; Colecchia M; Biasoni D; Catanzaro M; Stagni S; Torelli T; Necchi A; Piva L; Milani A; Salvioni R
    J Urol; 2011 Oct; 186(4):1298-302. PubMed ID: 21849196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
    Spiess PE; Brown GA; Liu P; Tu SM; Tannir NM; Evans JG; Kamat AM; Kassouf W; Pisters LL
    J Urol; 2007 Jan; 177(1):131-8. PubMed ID: 17162023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
    You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
    Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein.
    Peterson M; Beck S; Bihrle R; Einhorn L; Foster R
    BJU Int; 2009 Jul; 104(2):176-8. PubMed ID: 19493258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Spiess PE; Tannir NM; Tu SM; Brown GA; Liu P; Kamat AM; Wood CG; Evans JG; Pisters LL
    Cancer; 2007 Dec; 110(12):2700-8. PubMed ID: 17948916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
    Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.
    Spiess PE; Brown GA; Liu P; Tannir NM; Tu SM; Evans JG; Czerniak B; Kamat AM; Pisters LL
    Cancer; 2006 Oct; 107(7):1483-90. PubMed ID: 16944541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only.
    Nicolai N; Miceli R; Artusi R; Piva L; Pizzocaro G; Salvioni R
    J Urol; 2004 Jan; 171(1):172-6. PubMed ID: 14665870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance.
    Subramanian VS; Gilligan T; Klein EA
    Nat Clin Pract Urol; 2008 Apr; 5(4):220-3. PubMed ID: 18268549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical presentation of testicular germinal cancer].
    Fernández Gómez JM; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; Escaf Barmadah S; García Rodríguez J; Pérez García FJ; Rodríguez Faba O; Jalón Monzón A
    Arch Esp Urol; 2002 Oct; 55(8):915-22. PubMed ID: 12455282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy.
    Suurmeijer AJ; Oosterhuis JW; Marrink J; De Bruin HW; Schraffordt Koops H; Sleijfer DT; Fleuren GJ
    Oncodev Biol Med; 1983; 4(4):289-308. PubMed ID: 6188132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer.
    Nielsen ME; Lima G; Schaeffer EM; Porter J; Cadeddu JA; Tuerk I; Kavoussi LR
    Urology; 2007 Dec; 70(6):1168-72. PubMed ID: 18158040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor markers in testicular germ cell tumors related to the stage of the disease at the time of diagnosis.
    Jacobsen GK
    Oncodev Biol Med; 1983; 4(6):C39-44. PubMed ID: 6196749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
    Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the role of enlarged lymph node resection alone in patients with nonseminomatous germ cell tumor who had stage II or III disease?
    Ekenel M; Keskin S; Sanli Ö; Bavbek S; Tunç M; Ander H; Ozcan F; Kiliçaslan I; Başaran M
    Clin Genitourin Cancer; 2012 Sep; 10(3):185-9. PubMed ID: 22682983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: long-term oncologic outcomes.
    Finelli A
    Curr Opin Urol; 2008 Mar; 18(2):180-4. PubMed ID: 18303540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.